IRF4 and neoplasm: These data demonstrated that most signature T cell genes identified in Figure 5 were upregulated within the anti-PD-L1 treatment group in this model, including Tnfrsf4, Icos, Irf8, Chmp4b, and Irf4. This suggests that our T cell signatures identified through the Tg4 Nr4a3-Tocky model are faithful at discriminating T cell responses in an anti-PD-L1-responsive tumor model.